Novo Nordisk on Thursday launched an unsolicited bid valued at up to $9 billion for obesity-drug developer Metsera, hoping to ...

Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera , after Pfizer in ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.

U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales growth for its blockbuster obesity drug Wegovy, Doustdar has already ...

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Analysts say Pfizer could use its strong connections within the Trump administration to bolster its case, with CEO Albert ...

While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential ...

Pfizer says Novo Nordisk bid breaks law, calling the $9B Metsera offer an illegal attempt to eliminate a U.S. competitor with antitrust risks.